<?xml version="1.0" encoding="UTF-8"?>
<ref id="bb0145">
 <label>29</label>
 <element-citation publication-type="journal" id="rf0130">
  <person-group person-group-type="author">
   <name>
    <surname>Davey</surname>
    <given-names>R.T.</given-names>
    <suffix>Jr.</suffix>
   </name>
   <name>
    <surname>Fernandez-Cruz</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Markowitz</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Pett</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Babiker</surname>
    <given-names>A.G.</given-names>
   </name>
   <name>
    <surname>Wentworth</surname>
    <given-names>D.</given-names>
   </name>
  </person-group>
  <article-title>Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial</article-title>
  <source>Lancet Respir Med</source>
  <volume>7</volume>
  <year>2019</year>
  <fpage>951</fpage>
  <lpage>963</lpage>
  <pub-id pub-id-type="pmid">31582358</pub-id>
 </element-citation>
</ref>
